Study title:
Tebbi CK et al, Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin,, bleomycin, vincristine and etoposide (DBVE) and radiation: a Pediatric Oncology Group (POG) study, Pediatr Blood Cancer. 2006 Feb;46(2):198-202Tebbi CK et al, Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin,, bleomycin, vincristine and etoposide (DBVE) and radiation: a Pediatric Oncology Group (POG) study, Pediatr Blood Cancer. 2006 Feb;46(2):198-202
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Neoplasms [C04]
|
Brands: Please see report, Please see report, Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: CYCLOPHOSPHAMIDE |
ATC code: |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
Y
|